Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AMP nucleosidase (AMN) is an enzyme found exclusively in prokaryotes, such as Escherichia coli, where it catalyzes the hydrolysis of adenosine monophosphate (AMP) into adenine and ribose 5-phosphate[1][3][4][6]. This reaction plays a key role in the purine nucleoside salvage pathway and in regulating intracellular AMP concentrations. AMN is structurally a homohexamer, with each monomer containing a catalytic domain and a putative regulatory domain. Its activity is allosterically regulated: activated by ATP and inhibited by inorganic phosphate. AMN’s structure reveals similarity to nucleoside phosphorylases, placing it within that enzyme family, but with a unique regulatory domain. The enzyme is not present in higher eukaryotes and has no direct link to human diseases or existing drugs[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AMP nucleosidase (AMN).